polyclonal anti-thymocyte globulin (atg) is used as an immunosuppressive agent in the treatment of aplastic anemia (aa). serum sickness is a recognized side effect of atg. we observed abnormal skin manifestation in patient with aplastic anemia who had been treated with atg. we conclude that abnormal immune function caused by aplastic anemia and atg and corticosteroids may aggravate the signs of...

abstract background: lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients. the principle risk factors for development of ptld are the degree of overall immunosuppression and the ebv serostatus of the recipient. in this study, the risk of ptld in kidney transplant recipients who received anti- ly...

BACKGROUND A combination of horse anti-thymocyte globulin and cyclosporine produces responses in 60-70% of patients with severe aplastic anemia. We performed a phase II study of rabbit anti-thymocyte globulin and cyclosporine as first-line therapy for severe aplastic anemia. DESIGN AND METHODS Twenty patients with severe aplastic anemia treated with rabbit anti-thymocyte globulin were compare...

BACKGROUND Basiliximab and anti-thymocyte globulin are widely used drugs for induction therapy after pediatric heart transplantation. The aim of this study was to determine whether any differences could be observed between basiliximab and anti-thymocyte globulin, with respect to long-term mortality, in a population of pediatric cardiac transplant recipients. METHODS AND RESULTS An analysis of...

 Abstract Background: Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients. The principle risk factors for development of PTLD are the degree of overall immunosuppression and the EBV serostatus of the recipient. In this study, the risk of PTLD in kidney transplant recipients who received Anti- L...

Rabbit anti-thymocyte globulin is used worldwide to treat and prevent rejection in kidney transplantation. Multiple mechanisms of action of this polyclonal preparation are responsible for its success. Studies have supported clinical benefits of rabbit anti-thymocyte globulin in high immunological risk kidney transplant recipients when used as an induction agent at the time of transplant and for...

The impact of the intensity of graft-versus-host-disease immunoprophylaxis on transplantation outcomes in patients undergoing transplantation following reduced-intensity conditioning is unclear. This study addresses this issue in 228 adult patients above 50 years of age with acute myeloid leukemia in first complete remission given peripheral blood stem cells from HLA-identical siblings after fl...

Anti-thymocyte globulin is strongly reactive with platelets as measured by flow cytometric analysis. This reactivity appears to be independent of human leukocyte antigen (HLA) phenotype, is dose-dependent with saturation of platelet binding sites readily achieved with concentrations of horse anti-thymocyte globulin (ATG) at 0.25 mg per ml, and cannot be blocked with human anti-PLA1 antibody nor...